| Literature DB >> 12720524 |
Timothy J R Lambert1, David J Castle.
Abstract
Pharmacological treatment remains the mainstay of the management of schizophrenia. Older, "typical" antipsychotics carry a significant burden of side effects, notably extrapyramidal and neurocognitive side effects. Newer, "atypical" agents carry a lower risk of extrapyramidal side effects. They appear to have added benefit for treating negative and cognitive symptoms of schizophrenia, and hence can enhance the quality of life of some patients. The choice of particular agents for individual patients requires a balancing of efficacy and side effects. Medication is only one element of what should be an individualised comprehensive treatment plan for people with schizophrenia.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12720524 DOI: 10.5694/j.1326-5377.2003.tb05309.x
Source DB: PubMed Journal: Med J Aust ISSN: 0025-729X Impact factor: 7.738